These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
522 related articles for article (PubMed ID: 23507201)
1. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors. Vyas VK; Ghate M; Goel A J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201 [TBL] [Abstract][Full Text] [Related]
2. Ligand and structure-based approaches for the identification of SIRT1 activators. Vyas VK; Goel A; Ghate M; Patel P Chem Biol Interact; 2015 Feb; 228():9-17. PubMed ID: 25595223 [TBL] [Abstract][Full Text] [Related]
3. Identification of novel PfDHODH inhibitors as antimalarial agents via pharmacophore-based virtual screening followed by molecular docking and in vivo antimalarial activity. Vyas VK; Qureshi G; Ghate M; Patel H; Dalai S SAR QSAR Environ Res; 2016 Jun; 27(6):427-40. PubMed ID: 27310104 [TBL] [Abstract][Full Text] [Related]
4. Pharmacophore identification, virtual screening and biological evaluation of prenylated flavonoids derivatives as PKB/Akt1 inhibitors. Dong X; Zhou X; Jing H; Chen J; Liu T; Yang B; He Q; Hu Y Eur J Med Chem; 2011 Dec; 46(12):5949-58. PubMed ID: 22027102 [TBL] [Abstract][Full Text] [Related]
5. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors. Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012 [TBL] [Abstract][Full Text] [Related]
6. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies. Yu H; Wang Z; Zhang L; Zhang J; Huang Q Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906 [TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors. Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393 [TBL] [Abstract][Full Text] [Related]
8. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification. Islam MA; Pillay TS J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527 [TBL] [Abstract][Full Text] [Related]
9. Targeting the Akt1 allosteric site to identify novel scaffolds through virtual screening. Yilmaz OG; Olmez EO; Ulgen KO Comput Biol Chem; 2014 Feb; 48():1-13. PubMed ID: 24291487 [TBL] [Abstract][Full Text] [Related]
10. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas. Li HF; Lu T; Zhu T; Jiang YJ; Rao SS; Hu LY; Xin BT; Chen YD Eur J Med Chem; 2009 Mar; 44(3):1240-9. PubMed ID: 18947905 [TBL] [Abstract][Full Text] [Related]
11. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors. Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613 [TBL] [Abstract][Full Text] [Related]
12. Structure-based pharmacophore models to probe anticancer activity of inhibitors of protein kinase B-beta (PKB β). Akhtar N; Jabeen I; Jalal N; Antilla J Chem Biol Drug Des; 2019 Mar; 93(3):325-336. PubMed ID: 30354009 [TBL] [Abstract][Full Text] [Related]
13. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ). Davis GD; Vasanthi AH Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945 [TBL] [Abstract][Full Text] [Related]
14. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies. Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816 [TBL] [Abstract][Full Text] [Related]
15. Docking of protein kinase B inhibitors: implications in the structure-based optimization of a novel scaffold. Hernández-Campos A; Velázquez-Martínez I; Castillo R; López-Vallejo F; Jia P; Yu Y; Giulianotti MA; Medina-Franco JL Chem Biol Drug Des; 2010 Sep; 76(3):269-76. PubMed ID: 20572809 [TBL] [Abstract][Full Text] [Related]
16. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening. Chaudhari P; Bari S Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560 [TBL] [Abstract][Full Text] [Related]
17. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase. Bhojwani HR; Joshi UJ Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900 [TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel protein kinase B inhibitor by structure-based virtual screening. Medina-Franco JL; Giulianotti MA; Yu Y; Shen L; Yao L; Singh N Bioorg Med Chem Lett; 2009 Aug; 19(16):4634-8. PubMed ID: 19604696 [TBL] [Abstract][Full Text] [Related]
19. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors. Saxena S; Chaudhaery SS; Varshney K; Saxena AK SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581 [TBL] [Abstract][Full Text] [Related]
20. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors. Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]